If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksValiRx Regulatory News (VAL)

Share Price Information for ValiRx (VAL)

Share Price is delayed by 15 minutes
Get Live Data
0.16    -0.0105 (-6.16%)
Bid:
0.15
Ask:
0.17
Spread: 0.02 (13.333%)
Market Cap: £2.11m
VAL Live PriceLast checked at - London Stock Exchange

Intraday ValiRx Share Chart

Final Results

23 Jun 2005 14:42

AZURE HOLDINGS PLC PRELIMINARY ANNOUNCEMENT OF RESULTS YEAR ENDED 31 DECEMBER 2004 Chairman's StatementI am pleased to present my report for the year ended 31 December 2004.Your Company is still seeking a suitable merger target. During the period, theCompany entered into discussions with an acquisition target but the board couldnot agree commercial terms and talks were terminated.Your board is pursuing other acquisition targets which, owing to their size,may result in a reverse takeover.In the meantime, the directors have agreed not to draw their salaries and arefocused on keeping overheads to a minimum.Nicolas GreenstoneChairman23 June 2005Profit and loss accountfor the year ended 31 December 2004 Year ended Year ended 31 31 December December 2004 2003 ‚£'000 ‚£'000 Administrative expenses (345) (86) Profit on disposal of investments - 10 Operating loss (345) (76) Loss on disposal of subsidiary undertakings - (74) Loss on ordinary activities before taxation (345) (150) Taxation - - Loss on ordinary activities after taxation (345) (150) Loss per share (0.86p) (4.14p) Fully diluted loss per share (0.86p) (4.14p) The Group has no recognised gains and losses other than the loss for the year.Balance sheetas at 31 December 2004 2004 2003 ‚£'000 ‚£'000 Current assets Debtors 7 7 Cash at bank and in hand 14 119 21 126 Creditors: amounts falling due within one year (90) (59) Net current (liabilities)/assets (69) 67 Total assets less current liabilities (69) 67 Capital and reserves Called up share capital 5,475 5,304 Share premium account 10,279 10,241 Profit and loss account (15,823) (15,478) Equity shareholders' (deficit)/funds (69) 67 Cash flow statementfor the year ended 31 December 2004 2004 2003 ‚£'000 ‚£'000 Cash outflow from operating activities (225) (76) Financing Issue of equity shares 120 195 (Decrease)/increase in cash in the year (105) 119 Notes to the preliminary announcementfor the year ended 31 December 2004 1. Basis of preparation The financial information in this announcement does not constitute statutoryfinancial statements as defined in Section 240 of the Companies Act 1985. Theinformation relating to the year ended 31 December 2003 is an extract from thestatutory accounts for that year, which have been delivered to the Registrar ofCompanies. The auditors' report on those accounts was unqualified and did notcontain any statement under section 237(2) or (3) of the Companies Act 1985.The auditors have indicated that they will issue an unqualified report on thestatutory financial statements for the year ended 31 December 2004. Copies ofthe Company's Report and Financial Statements will be sent to shareholdersshortly and will be available at the registered office of the Company: OneGreat Cumberland Place, London W1H 7AL . 2. Going concern The financial statements have been prepared on a going concern basis inaccordance with applicable United Kingdom Accounting Standards.The directors have adopted this basis as they consider that the company hassufficient working capital to meet its obligations as they fall due.Chiddingfold Investments Limited, has agreed to fund the company's workingcapital requirements for a period until 30 June 2006, to the extent that suchcosts are not covered by other fund raisings or reverse acquisitiontransactions.During the year the Company made losses of ‚£345,000 and had net liabilities at31 December 2004 of ‚£69,000.The directors continue to actively seek suitable targets for a reverseacquisition.The directors have therefore prepared the financial statements on the goingconcern basis. The financial statements do not include any adjustments thatmight arise if this basis was inappropriate. 3. Basis of consolidation The consolidated financial statements include the financial statements of theCompany and have been prepared using both merger accounting principles andacquisition accounting principles.The Company has not presented its own profit and loss account as permitted bySection 230(3) of the Companies Act 1985. The Company's loss for the financialyear was ‚£345,000.4. Loss per shareLoss per share are calculated on a net basis using the loss on ordinaryactivities and the weighted average number of shares detailed below.In calculating fully diluted loss per share, the weighted average number ofshares is adjusted for the effect of dilutive share options issued under Groupshare option schemes. 2004 2003 ‚£'000 ‚£'000 Basic and diluted losses attributable to ordinary (345) (150)shareholders Number Number Weighted average number of ordinary shares 39,767,965 3,625,812 Dilutive share options - - Adjusted weighted average number of ordinary shares 39,767,965 3,625,812 Loss per share (0.86p) (4.14p) Fully diluted loss per share (0.86p) (4.14p) 5. Reconciliation of operating loss to net cash outflow from operating activities 2004 2003 ‚£'000 ‚£'000 Operating loss (345) (76) Decrease in debtors - 48 Increase/(decrease) in creditors 31 (48) Creditor settled via issue of shares 89 - Net cash outflow from operating activities (225) (76) 6. Reserves Share Profit and Total premium loss account account ‚£'000 ‚£'000 ‚£'000 At 1 January 2004 10,241 (15,478) (5,237) Loss for the year - (345) (345) Issue of shares 38 - 38 At 31 December 2004 10,279 (15,823) (5,544) 7. Taxation Factors affecting taxation:The tax charge for the year does not equate to the loss before tax at thestandard rate of corporation tax in the United Kingdom (30%). The differencesare explained below: 2004 2003 ‚£'000 ‚£'000 Loss on ordinary activities before taxation (345) (150) Loss on ordinary activities multiplied by the (104) (45)standard rate of corporation tax in the United Kingdom of 30% (2003: 30%) Effect of non-deductible expenses and addition to 104 45tax losses - - At 31 December 2004, the company had accumulated tax losses of ‚£817,627 arisingform management expenses and ‚£1,476,749 of capital losses. 8. Dividends The Directors are not proposing the payment of a dividend in respect of theyear ended 31 December, 2004.ENDAZURE HOLDINGS PLC
Date   Source Headline
29th May 20097:00 amRNSPlacing Summary and Total Voting Rights
11th May 20097:00 amRNSIssue of Equity
5th May 20091:00 pmRNSIssue of Equity
30th Apr 20097:00 amRNSTotal Voting Rights
27th Apr 20097:00 amRNSIssue of Equity
16th Apr 20093:05 pmRNSHolding(s) in Company
16th Apr 20097:00 amRNSIssue of Equity
9th Apr 20097:00 amRNSIssue of Equity
6th Apr 20099:59 amRNSHolding(s) in Company
31st Mar 20097:00 amRNSUpdate to the Sale of Shares Agreement
31st Mar 20097:00 amRNSIssue of Equity and Directors' Shareholdings
12th Mar 20097:00 amRNSValiRx Announces Promising In Vivo Data
27th Feb 20097:00 amRNSTotal Voting Rights
13th Feb 200910:52 amRNSResult of EGM
30th Jan 20097:00 amRNSTotal Voting Rights
29th Jan 200912:07 pmRNSAvailability of circular
28th Jan 200911:55 amRNSProposed Reorganisation and General Meeting
5th Jan 20092:50 pmRNSIssue of Equity
31st Dec 20089:00 amRNSTotal Voting Rights
15th Dec 20087:00 amRNSGlobal Distribution Agreement
5th Dec 20082:00 pmRNSChange of Adviser
27th Nov 20084:19 pmRNSIssue of Equity
16th Sep 20087:00 amRNSUpdate on cancer detection test
11th Sep 20087:00 amRNSInterim Results
10th Sep 200810:33 amRNSNotice of Results
18th Aug 20084:02 pmRNSAppointment of director
31st Jul 20087:00 amRNSTotal Voting Rights
28th Jul 20082:48 pmRNSAGM Statement
23rd Jul 20084:02 pmRNSDirector's Dealing
14th Jul 20082:23 pmRNSDirector/PDMR Shareholding
14th Jul 20087:00 amRNSValiRx acquires Cronos Therap
9th Jul 20087:00 amRNSValiRx Acquires Global Rights
30th Jun 20084:38 pmRNSJoint Broker Appointment
30th Jun 20087:00 amRNSFinal Results
26th Jun 20087:00 amRNSTherapeutic Pipeline - in viv
23rd Jun 20088:00 amRNSNotice of Results
5th Jun 20089:13 amRNSHolding(s) in Company
30th May 20087:00 amRNSTotal Voting Rights
15th May 200812:37 pmRNSHolding(s) in Company
12th May 20084:42 pmPRNStatement re Placing of Shares
8th May 20088:05 amRNSIssue of Equity
7th May 20082:20 pmRNSHolding(s) in Company
2nd May 200811:35 amRNSResult of EGM
30th Apr 20087:00 amRNSTotal Voting Rights
7th Apr 20085:13 pmRNSNotice of EGM and Placing
18th Mar 20087:50 amPRNValibio Research Update
13th Feb 20087:55 amPRNLetter of Intent
29th Jan 20087:00 amPRNAustralian GeneICE Patent Granted
23rd Jan 20087:00 amPRNMorphogenesis Update
17th Jan 20087:00 amPRNGeneICE – CRT Research Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.